Table 5 Frequency of treatment-emergent adverse events leading to dose reduction in more than one patient in any treatment group (safety population)
Placebo (N= 112) | 25 mg/d Neramexane (N= 108) | 50 mg/d Neramexane (N= 107) | 75 mg/d Neramexane (N= 102) | |||||
|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |
Any adverse event | 4 | 3.6 | 7 | 6.5 | 9 | 8.4 | 21 | 20.6 |
Dizziness | 1 | 0.9 | 2 | 1.9 | 7 | 6.5 | 15 | 14.7 |
Vertigo | 0 | 0.0 | 1 | 0.9 | 2 | 1.9 | 5 | 4.9 |
Nausea | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 2.0 |
Fatigue | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 2.9 |